Sodium citrate

CAS No. 68-04-2

Sodium citrate( —— )

Catalog No. M35842 CAS No. 68-04-2

Sodium citrate (Natrocitral) is the sodium salt of citric acid.Citric acid trisodium induces apoptosis and cell cycle arrest at G2/M phase and S phase.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
500MG 38 In Stock
1G 45 In Stock

Biological Information

  • Product Name
    Sodium citrate
  • Note
    Research use only, not for human use.
  • Brief Description
    Sodium citrate (Natrocitral) is the sodium salt of citric acid.Citric acid trisodium induces apoptosis and cell cycle arrest at G2/M phase and S phase.
  • Description
    Citric acid trisodium is a natural preservative and food tartness enhancer. Citric acid trisodium induces apoptosis and cell cycle arrest at G2/M phase and S phase. Citric acid trisodium cause oxidative damage of the liver by means of the decrease of antioxidative enzyme activities. Citric acid trisodium causes renal toxicity in mice.
  • In Vitro
    Citric acid trisodium (0-12.5 mM; 24 h) shows antiproliferative activity in a dose dependent manner.Citric acid trisodium (12.5 mM; 72 h) induces apoptosis and cell cycle arrest at G2/M phase and S phase in a dosedependent manner.Citric acid trisodium (12.5 mM; 48 h) increases the expression of FAS, BAX, BID, AIF, EndoG, cytochrome c, PARP, GADD153, GRP78 and caspase-3, -8, -9, and decreases of BCL-2 and BCL-Xl..Cell Viability Assay Cell Line:HaCaT cells Concentration:0, 2.5, 5, 7.5, 10, 12.5 mM Incubation Time:24 h Result:Inhibited the cell viability in a dose dependent manner.Cell Cycle Analysis Cell Line:HaCaT cells Concentration:12.5 mM Incubation Time:0, 12, 24, 48, 72 h Result:Induced apoptosis and cell cycle arrest at G2/M phase and S phase in a dosedependent manner.Western Blot Analysis Cell Line:HaCaT cells Concentration:12.5 mM Incubation Time:12, 24, 48 h Result:Increased the expression of FAS, BAX, BID, AIF, EndoG, cytochrome c, PARP, GADD153, GRP78 and caspase-3, -8, -9, and decreased of BCL-2 and BCL-Xl.
  • In Vivo
    Citric acid trisodium (120, 240, and 480 mg/kg; i.p.) significantly decreases GSH-Px activity and induces an increase in the MDA (malonyldialdehyde) levels in mouse liver.Citric acid trisodium (120, 240, and 480 mg/kg; i.p.) induces apoptosis by increases caspase-3 activity in a dose-dependent manner in mouse hepatocytes.Citric acid trisodium (120, 240, and 480 mg/kg; i.p.; weekly for 3 weeks) causes renal toxicity in mice.Animal Model:20 g male Kunming mice Dosage:120, 240, 480 mg/kg Administration:I.p.; weekly for 3 weeks Result:T-SOD and GSH-Px activities in the treated groups decreased with increasing doses of citric acid, NOS activity tended to increase, and H2O2 and MDA contents gradually decreased.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    68-04-2
  • Formula Weight
    258.07
  • Molecular Formula
    C6H5Na3O7
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?H2O : 50 mg/mL (193.75 mM; Ultrasonic)
  • SMILES
    C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Na+].[Na+].[Na+]
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Chen X, et al. Study on injury effect of food additive citric acid on liver tissue in mice. Cytotechnology. 2014 Mar;66(2):275-82.?
molnova catalog
related products
  • Lasmiditan

    Lasmiditan, also known as COL-144 and LY573144, is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist (K1=2.21 μM) without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study.

  • Mogroside III

    Mogroside III is a triterpenoid glycoside and a nonsugar sweetener. Mogroside III is transformed by human intestinal bacteria to release secondary glycoside mogroside IIA1 and aglycone mogrol.

  • 3,4,5-Tricaffeoylqui...

    3,4,5-Tricaffeoylquinic acid may attenuate the TNF-α±- and LPS-stimulated production of inflammatory mediators in keratinocytes by suppressing the Toll-like receptor 4 expression-mediated activation of the Akt, ERK and NF-κB pathways, it may exert an inhibitory effect against the pro-inflammatory mediator-induced skin disease.